{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:36:27Z","timestamp":1791146187436,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>High serum total cholesterol and low\u2010density lipoprotein (LDL) levels have been demonstrated to increase the probability of a sustained viral response (SVR) in chronic hepatitis C. Conversely, insulin resistance reduces SVR rates. We investigated the influence of baseline glucose and lipid values on the outcome of hepatitis C virus (HCV) treatment in HIV\u20101 infected subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively reviewed the charts of HIV\/HCV\u2010coinfected patients treated with an interferon\u2010based regimen from 2002 to 2008. Fasting glucose levels and total cholesterol, LDL and triglyceride levels were recorded prior to the initiation of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 96 patients enrolled in the study, 36 (37.5%) had genotype 1, 48 (50%) genotype 2 or 3 and 12 (12.5%) genotype 4. SVR was obtained in 25% (nine of 36) and 70% (42 of 60) of patients with genotype 1 and other genotypes, respectively. In the multivariate analysis, the independent predictors of SVR were: genotype other than genotype 1 [adjusted odds ratio 9.64, confidence interval (CI) 2.7\u201334.3; <jats:italic>P<\/jats:italic>&lt;0.0001], HCV viraemia [adjusted odds ratio 0.36, CI 0.15\u20130.9; <jats:italic>P<\/jats:italic>=0.028], fasting glucose \u2265100\u2003mg\/dL [adjusted odds ratio 0.13, CI 0.034\u20130.51; <jats:italic>P<\/jats:italic>=0.003], and cholesterol level \u2265190\u2003mg\/dL [adjusted odds ratio 5.96, CI 1.6\u201322.3; <jats:italic>P<\/jats:italic>=0.008].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Higher baseline serum glucose and cholesterol levels may be significant prognostic indicators for anti\u2010HCV treatment outcome in HIV\/HCV\u2010coinfected patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00729.x","type":"journal-article","created":{"date-parts":[[2009,7,2]],"date-time":"2009-07-02T02:29:23Z","timestamp":1246501763000},"page":"580-585","source":"Crossref","is-referenced-by-count":9,"title":["Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV\/HCV\u2010coinfected patients"],"prefix":"10.1111","volume":"10","author":[{"given":"M","family":"Cesari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Caramma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Adorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Milazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,9,22]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199912240-00002"},{"key":"e_1_2_5_3_2","first-page":"428","article-title":"Hepatitis C virus induced hypobetalipoproteinemia","volume":"34","author":"Serfaty L","year":"2001","journal-title":"a possible mechanism for steatosis in chronic hepatitis C"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03000.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-8-200010170-00009"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50291"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i44.7075"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.12.049"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.11.022"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.01038.x"},{"key":"e_1_2_5_11_2","first-page":"2375","article-title":"European guidelines on cardiovascular disease prevention in clinical practice","volume":"28","author":"Graham I","year":"2007","journal-title":"executive summary"},{"issue":"5","key":"e_1_2_5_12_2","first-page":"57","article-title":"Proposal for a clinic classification of morphological and metabolic alterations under ART","volume":"5","author":"Galli M","year":"2000","journal-title":"Antiviral Ther"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282fbd1c4"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21261"},{"key":"e_1_2_5_16_2","first-page":"403","article-title":"Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype","volume":"46","author":"Akuta N","year":"2007","journal-title":"amino acid substitutions in the core region and low-density lipoprotein cholesterol levels 1b"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040842"},{"key":"e_1_2_5_18_2","first-page":"1","article-title":"TNF\u2010\u03b1, chronic hepatitis C and diabetes","volume":"98","author":"Knobler H","year":"2005","journal-title":"a novel triad"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63408-6"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.11.016"},{"key":"e_1_2_5_21_2","first-page":"320","article-title":"Hepatitis C, metabolic syndrome, and inflammatory markers","volume":"75","author":"Shaheen M","year":"2007","journal-title":"results from the Third National Health and Nutrition Examination Survey [NHANES III]"},{"key":"e_1_2_5_22_2","first-page":"99","article-title":"Dysmetabolic changes associated with HCV","volume":"3","author":"Lonardo A","year":"2008","journal-title":"a distinct syndrome?"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282efad32"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/496981"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_5_26_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/135965350601100405","article-title":"Influence of hepatitis C genotypes on lipid levels in HIV\u2010positive patients during highly active antiretroviral therapy","volume":"11","author":"Lapadula G","year":"2006","journal-title":"Antivir Ther"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2006.00416.x"},{"key":"e_1_2_5_28_2","first-page":"2621","article-title":"Incidence of adipose tissue alterations in first\u2010line antiretroviral therapy","volume":"162","author":"Galli M","year":"2002","journal-title":"the LipoICoNa Study"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440280120012"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.22.12766"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.14.6919-6928.2002"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00729.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00729.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:57:24Z","timestamp":1696870644000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00729.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,22]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00729.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00729.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,22]]}}}